Cargando…

A community survey of coverage and adverse events following country-wide triple-drug mass drug administration for lymphatic filariasis elimination, Samoa 2018

The Global Programme to Eliminate Lymphatic Filariasis has made considerable progress but is experiencing challenges in meeting targets in some countries. Recent World Health Organization guidelines have recommended two rounds of triple-drug therapy with ivermectin, diethylcarbamazine (DEC), and alb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willis, Gabriela A., Mayfield, Helen J., Kearns, Therese, Naseri, Take, Thomsen, Robert, Gass, Katherine, Sheridan, Sarah, Graves, Patricia M., Lau, Colleen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7728255/ https://www.ncbi.nlm.nih.gov/pubmed/33253148 http://dx.doi.org/10.1371/journal.pntd.0008854

Ejemplares similares

Supporting elimination of lymphatic filariasis in Samoa by predicting locations of residual infection using machine learning and geostatistics
por: Mayfield, Helen J., et al.
Publicado: (2020)

Scabies prevalence after ivermectin-based mass drug administration for lymphatic filariasis, Samoa 2018–2019
por: Willis, Gabriela A., et al.
Publicado: (2023)

Triple-Drug Treatment Is Effective for Lymphatic Filariasis Microfilaria Clearance in Samoa
por: Graves, Patricia M., et al.
Publicado: (2021)

Lymphatic filariasis epidemiology in Samoa in 2018: Geographic clustering and higher antigen prevalence in older age groups
por: Lau, Colleen L., et al.
Publicado: (2020)

Evaluating Molecular Xenomonitoring as a Tool for Lymphatic Filariasis Surveillance in Samoa, 2018–2019
por: McPherson, Brady, et al.
Publicado: (2022)

Lymphatic Filariasis Elimination in American Samoa: Evaluation of Molecular Xenomonitoring as a Surveillance Tool in the Endgame
por: Lau, Colleen L., et al.
Publicado: (2016)

Comparison of Immunochromatographic Test (ICT) and Filariasis Test Strip (FTS) for Detecting Lymphatic Filariasis Antigen in American Samoa, 2016
por: Sheel, Meru, et al.
Publicado: (2021)

Burden of hydrocoele assessed from medical and surgical records in a lymphatic filariasis endemic country, Samoa
por: Ah Leong-Lui, Tile A., et al.
Publicado: (2019)

Spatially Explicit Environmental Factors Associated with Lymphatic Filariasis Infection in American Samoa
por: Lemin, Morgan E., et al.
Publicado: (2022)

Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016
por: Sheel, Meru, et al.
Publicado: (2018)

Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration
por: Lau, Colleen L., et al.
Publicado: (2017)

Seroprevalence and Spatial Epidemiology of Lymphatic Filariasis in American Samoa after Successful Mass Drug Administration
por: Lau, Colleen L., et al.
Publicado: (2014)

Prevalence and risk factors associated with lymphatic filariasis in American Samoa after mass drug administration
por: Coutts, Shaun P., et al.
Publicado: (2017)

Potential use of antibodies to provide an earlier indication of lymphatic filariasis resurgence in post–mass drug ad ministration surveillance in American Samoa
por: Cadavid Restrepo, Angela M., et al.
Publicado: (2022)

Demographic, socioeconomic and disease knowledge factors, but not population mobility, associated with lymphatic filariasis infection in adult workers in American Samoa in 2014
por: Graves, Patricia M., et al.
Publicado: (2020)

Potential strategies for strengthening surveillance of lymphatic filariasis in American Samoa after mass drug administration: Reducing ‘number needed to test’ by targeting older age groups, hotspots, and household members of infected persons
por: Lau, Colleen L., et al.
Publicado: (2020)

Lymphatic filariasis endgame strategies: Using GEOFIL to model mass drug administration and targeted surveillance and treatment strategies in American Samoa
por: Shaw, Callum, et al.
Publicado: (2023)

The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific
por: Rainima-Qaniuci, Merelesita, et al.
Publicado: (2022)

Lymphatic filariasis in 2016 in American Samoa: Identifying clustering and hotspots using non-spatial and three spatial analytical methods
por: Wangdi, Kinley, et al.
Publicado: (2022)

Spatial predictive risk mapping of lymphatic filariasis residual hotspots in American Samoa using demographic and environmental factors
por: Cadavid Restrepo, Angela M., et al.
Publicado: (2023)

Are we nearly there yet? Coverage and compliance of mass drug administration for lymphatic filariasis elimination
por: Alexander, Neal D. E.
Publicado: (2015)

Comparison of antigen and antibody responses in repeat lymphatic filariasis transmission assessment surveys in American Samoa
por: Won, Kimberly Y., et al.
Publicado: (2018)

Molecular Xenomonitoring Using Mosquitoes to Map Lymphatic Filariasis after Mass Drug Administration in American Samoa
por: Schmaedick, Mark A., et al.
Publicado: (2014)

Application of the Filariasis CELISA Antifilarial IgG(4) Antibody Assay in Surveillance in Lymphatic Filariasis Elimination Programmes in the South Pacific
por: Joseph, Hayley, et al.
Publicado: (2011)

An Evaluation of Coverage and Compliance of Mass Drug Administration 2006 for Elimination of Lymphatic Filariasis in Endemic Areas of Gujarat
por: Kumar, Pradeep, et al.
Publicado: (2008)

National Mass Drug Administration Costs for Lymphatic Filariasis Elimination
por: Goldman, Ann S., et al.
Publicado: (2007)

Elimination of lymphatic filariasis: current perspectives on mass drug administration
por: Gyapong, John O, et al.
Publicado: (2018)

Impact of mass drug administration for elimination of lymphatic filariasis in Nepal
por: Ojha, Chet Raj, et al.
Publicado: (2017)

Introduction of Triple-Drug Therapy for Accelerating Lymphatic Filariasis Elimination in India: Lessons Learned
por: Tripathi, Bhupendra, et al.
Publicado: (2022)

Elimination of Lymphatic Filariasis in The Gambia
por: Rebollo, Maria P., et al.
Publicado: (2015)

Coverage and Awareness of and Compliance with Mass Drug Administration for Elimination of Lymphatic Filariasis in Burdwan District, West Bengal, India
por: Roy, Rabindra Nath, et al.
Publicado: (2013)

Coverage of mass drug administration (MDA) and operational issues in elimination of lymphatic filariasis in selected districts of Jharkhand, India
por: Kumar, Dhananjay, et al.
Publicado: (2023)

The Global Programme to Eliminate Lymphatic Filariasis: History and achievements with special reference to annual single-dose treatment with diethylcarbamazine in Samoa and Fiji
por: Kimura, Eisaku
Publicado: (2011)

Overview of PacELF—the Pacific Programme for the Elimination of Lymphatic Filariasis
por: Ichimori, Kazuyo, et al.
Publicado: (2017)

Factors determining noncompliance to mass drug administration for lymphatic filariasis elimination
por: Nujum, Zinia T, et al.
Publicado: (2012)

A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery
por: Weil, Gary J, et al.
Publicado: (2020)

Compressing the Timelines for Development and Delivery: Accelerating Access to Triple-Drug Therapy to Eliminate Lymphatic Filariasis
por: Jacobson, Julie
Publicado: (2022)

Impact of the Lymphatic Filariasis Control Program towards elimination of filariasis in Vanuatu, 1997–2006
por: Allen, Tammy, et al.
Publicado: (2017)

Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance
por: Hussain, Mohammad A, et al.
Publicado: (2014)

Increasing Coverage in Mass Drug Administration for Lymphatic Filariasis Elimination in an Urban Setting: a Study of Malindi Town, Kenya
por: Njomo, Doris W., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_8kuin5kg3l5etll3nvu0vjb3ab